Tyler Van Buren
Stock Analyst at TD Cowen
(1.59)
# 3,243
Out of 4,876 analysts
57
Total ratings
39.13%
Success rate
-6.25%
Average return
Main Sectors:
Stocks Rated by Tyler Van Buren
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGON CG Oncology | Initiates: Buy | n/a | $25.96 | - | 1 | Jan 7, 2025 | |
| KROS Keros Therapeutics | Downgrades: Hold | n/a | $13.49 | - | 2 | Dec 12, 2024 | |
| BHVN Biohaven | Maintains: Buy | $55 → $75 | $14.09 | +432.29% | 2 | Nov 13, 2024 | |
| BCAX Bicara Therapeutics | Initiates: Buy | n/a | $8.71 | - | 1 | Oct 8, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Buy | n/a | $11.12 | - | 1 | Sep 16, 2024 | |
| MRNA Moderna | Maintains: Hold | $70 → $60 | $27.16 | +120.91% | 6 | Sep 13, 2024 | |
| ARTV Artiva Biotherapeutics | Initiates: Buy | n/a | $1.47 | - | 1 | Aug 13, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | n/a | $10.68 | - | 1 | Aug 6, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,030 → $1,200 | $521.00 | +130.33% | 7 | Jul 23, 2024 | |
| TECX Tectonic Therapeutic | Initiates: Buy | n/a | $19.77 | - | 1 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $18.57 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $85 | $110.67 | -23.20% | 5 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $30 | $47.49 | -36.83% | 2 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.19 | - | 1 | Dec 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $15.23 | - | 1 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $65.35 | - | 1 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $43.37 | - | 1 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $14.78 | +103.05% | 1 | May 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $44.86 | - | 1 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.04 | - | 2 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $70 | $31.15 | +124.72% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.18 | - | 1 | Jul 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $7.54 | - | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $9.10 | - | 1 | Oct 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $1.73 | +2,790.17% | 1 | Mar 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $225 | $16.60 | +1,255.42% | 1 | Feb 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $875 | $7.27 | +11,944.05% | 1 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $4.00 | +900.00% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $11.64 | +243.64% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $30 | $11.22 | +167.50% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $0.26 | +22,835.78% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $1.25 | +3,900.00% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $1.25 | +2,300.00% | 1 | Apr 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $140 → $200 | $2.33 | +8,502.15% | 1 | Jan 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.19 | - | 1 | Nov 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $16.76 | - | 1 | Aug 4, 2017 |
CG Oncology
Jan 7, 2025
Initiates: Buy
Price Target: n/a
Current: $25.96
Upside: -
Keros Therapeutics
Dec 12, 2024
Downgrades: Hold
Price Target: n/a
Current: $13.49
Upside: -
Biohaven
Nov 13, 2024
Maintains: Buy
Price Target: $55 → $75
Current: $14.09
Upside: +432.29%
Bicara Therapeutics
Oct 8, 2024
Initiates: Buy
Price Target: n/a
Current: $8.71
Upside: -
Oruka Therapeutics
Sep 16, 2024
Initiates: Buy
Price Target: n/a
Current: $11.12
Upside: -
Moderna
Sep 13, 2024
Maintains: Hold
Price Target: $70 → $60
Current: $27.16
Upside: +120.91%
Artiva Biotherapeutics
Aug 13, 2024
Initiates: Buy
Price Target: n/a
Current: $1.47
Upside: -
Cartesian Therapeutics
Aug 6, 2024
Initiates: Buy
Price Target: n/a
Current: $10.68
Upside: -
Regeneron Pharmaceuticals
Jul 23, 2024
Maintains: Buy
Price Target: $1,030 → $1,200
Current: $521.00
Upside: +130.33%
Tectonic Therapeutic
Jun 24, 2024
Initiates: Buy
Price Target: n/a
Current: $19.77
Upside: -
May 15, 2024
Initiates: Buy
Price Target: n/a
Current: $18.57
Upside: -
Apr 26, 2024
Maintains: Buy
Price Target: $90 → $85
Current: $110.67
Upside: -23.20%
Dec 11, 2023
Downgrades: Underperform
Price Target: $30
Current: $47.49
Upside: -36.83%
Dec 5, 2023
Initiates: Outperform
Price Target: n/a
Current: $4.19
Upside: -
Nov 29, 2023
Initiates: Outperform
Price Target: n/a
Current: $15.23
Upside: -
Oct 30, 2023
Initiates: Outperform
Price Target: n/a
Current: $65.35
Upside: -
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $43.37
Upside: -
May 22, 2023
Initiates: Outperform
Price Target: $30
Current: $14.78
Upside: +103.05%
Feb 6, 2023
Initiates: Outperform
Price Target: n/a
Current: $44.86
Upside: -
Jan 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.04
Upside: -
Aug 8, 2022
Initiates: Outperform
Price Target: $70
Current: $31.15
Upside: +124.72%
Jul 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $1.18
Upside: -
Dec 7, 2021
Initiates: Outperform
Price Target: n/a
Current: $7.54
Upside: -
Oct 11, 2021
Initiates: Outperform
Price Target: n/a
Current: $9.10
Upside: -
Mar 4, 2021
Initiates: Overweight
Price Target: $50
Current: $1.73
Upside: +2,790.17%
Feb 10, 2021
Initiates: Overweight
Price Target: $225
Current: $16.60
Upside: +1,255.42%
Nov 10, 2020
Initiates: Overweight
Price Target: $875
Current: $7.27
Upside: +11,944.05%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $4.00
Upside: +900.00%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $11.64
Upside: +243.64%
Aug 10, 2020
Maintains: Overweight
Price Target: $35 → $30
Current: $11.22
Upside: +167.50%
Jun 29, 2020
Initiates: Overweight
Price Target: $60
Current: $0.26
Upside: +22,835.78%
Jun 29, 2020
Initiates: Overweight
Price Target: $50
Current: $1.25
Upside: +3,900.00%
Apr 22, 2020
Initiates: Overweight
Price Target: $30
Current: $1.25
Upside: +2,300.00%
Jan 13, 2020
Reiterates: Overweight
Price Target: $140 → $200
Current: $2.33
Upside: +8,502.15%
Nov 2, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $3.19
Upside: -
Aug 4, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $16.76
Upside: -